Plasma N-Terminal Pro–Brain Natriuretic Peptide and Adrenomedullin
- 19 May 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 97 (19) , 1921-1929
- https://doi.org/10.1161/01.cir.97.19.1921
Abstract
Background —Newly discovered circulating peptides, N-terminal pro–brain natriuretic peptide (N-BNP) and adrenomedullin (ADM), were examined for prediction of cardiac function and prognosis and compared with previously reported markers in 121 patients with myocardial infarction. Methods and Results —The association between radionuclide left ventricular ejection fraction (LVEF) and N-BNP at 2 to 4 days ( r =−.63, P <.0001) and 3 to 5 months ( r =−.58, P <.0001) after infarction was comparable to that for C-terminal BNP and far stronger than for ADM ( r =−.26, P <.01), N-terminal atrial natriuretic peptide (N-ANP), C-terminal ANP, cGMP, or plasma catecholamine concentrations. For prediction of death over 24 months of follow-up, an early postinfarction N-BNP level ≥160 pmol/L had sensitivity, specificity, positive predictive value, and negative predictive values of 91%, 72%, 39%, and 97%, respectively, and was superior to any other neurohormone measured and to LVEF. Only 1 of 21 deaths occurred in a patient with an N-BNP level below the group median (Kaplan-Meier survival analysis, P <.00001). For prediction of heart failure (left ventricular failure), plasma N-BNP ≥ 145 pmol/L had sensitivity (85%) and negative predictive value (91%) comparable to the other cardiac peptides and was superior to ADM, plasma catecholamines, and LVEF. By multivariate analysis, N-BNP but not ADM provided predictive information for death and left ventricular failure independent of patient age, sex, LVEF, levels of other hormones, and previous history of heart failure, myocardial infarction, hypertension, or diabetes. Conclusions —Plasma N-BNP measured 2 to 4 days after myocardial infarction independently predicted left ventricular function and 2-year survival. Stratification of patients into low- and high-risk groups can be facilitated by plasma N-BNP or BNP measurements, and one of these could reasonably be included in the routine clinical workup of patients after myocardial infarction.Keywords
This publication has 31 references indexed in Scilit:
- Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular HypertrophyHypertension, 1996
- Diagnostic Value of B-Type Natriuretic Peptide Concentrations in Patients With Acute Myocardial InfarctionPublished by Elsevier ,1996
- Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunctionThe American Journal of Cardiology, 1996
- Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failureThe American Journal of Cardiology, 1995
- The Amino-Terminal Portion of Pro-Brain Natriuretic Peptide (Pro-BNP) Circulates in Human PlasmaBiochemical and Biophysical Research Communications, 1995
- Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasmaFEBS Letters, 1994
- Prognostic value of plasma atrial natriuretic factor, norepinephrine and epinephrine in acute myocardial infarctionThe American Journal of Cardiology, 1993
- Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarctionPublished by Elsevier ,1993
- Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart FailureNew England Journal of Medicine, 1984
- II. Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in manLife Sciences, 1981